MXPA05004219A - Composicion farmaceutica de liberacion prolongada. - Google Patents
Composicion farmaceutica de liberacion prolongada.Info
- Publication number
- MXPA05004219A MXPA05004219A MXPA05004219A MXPA05004219A MXPA05004219A MX PA05004219 A MXPA05004219 A MX PA05004219A MX PA05004219 A MXPA05004219 A MX PA05004219A MX PA05004219 A MXPA05004219 A MX PA05004219A MX PA05004219 A MXPA05004219 A MX PA05004219A
- Authority
- MX
- Mexico
- Prior art keywords
- cefquinome
- prolonged release
- composition
- oil
- formulations
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical group N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 claims abstract description 72
- 229950009592 cefquinome Drugs 0.000 claims abstract description 69
- 241001465754 Metazoa Species 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims description 107
- KYOHRXSGUROPGY-OFNLCGNNSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical group OS(O)(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 KYOHRXSGUROPGY-OFNLCGNNSA-N 0.000 claims description 33
- 229940083916 aluminum distearate Drugs 0.000 claims description 24
- RDIVANOKKPKCTO-UHFFFAOYSA-K aluminum;octadecanoate;hydroxide Chemical compound [OH-].[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RDIVANOKKPKCTO-UHFFFAOYSA-K 0.000 claims description 24
- 229930186147 Cephalosporin Natural products 0.000 claims description 18
- 229940124587 cephalosporin Drugs 0.000 claims description 18
- 150000001780 cephalosporins Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 abstract description 29
- -1 aluminium distearate Chemical compound 0.000 abstract description 12
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 230000036470 plasma concentration Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 63
- 241000283690 Bos taurus Species 0.000 description 27
- 230000037396 body weight Effects 0.000 description 27
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 238000007920 subcutaneous administration Methods 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 241000282887 Suidae Species 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 8
- 229940063655 aluminum stearate Drugs 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 6
- 229940093471 ethyl oleate Drugs 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 3
- 229960001139 cefazolin Drugs 0.000 description 3
- 229960004261 cefotaxime Drugs 0.000 description 3
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 3
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241001293418 Mannheimia haemolytica Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000004182 Tylosin Substances 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940116333 ethyl lactate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 2
- 229960004059 tylosin Drugs 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241001621404 Aulopidae Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N Cephalosporin C Natural products S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000351683 Macrocephenchelys brachialis Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000228417 Sarocladium strictum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PYMGGGYYAVKIJL-UHFFFAOYSA-K aluminum hexadecanoate dihydroxide Chemical compound [OH-].[OH-].[Al+3].CCCCCCCCCCCCCCCC([O-])=O PYMGGGYYAVKIJL-UHFFFAOYSA-K 0.000 description 1
- JJCSYJVFIRBCRI-UHFFFAOYSA-K aluminum;hexadecanoate Chemical compound [Al].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O JJCSYJVFIRBCRI-UHFFFAOYSA-K 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- HOKIDJSKDBPKTQ-GLXFQSAKSA-M cephalosporin C(1-) Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H]([NH3+])C([O-])=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-M 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940041010 fourth-generation cephalosporins Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02079477 | 2002-10-25 | ||
| PCT/EP2003/011644 WO2004037265A1 (en) | 2002-10-25 | 2003-10-20 | Prolonged release pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05004219A true MXPA05004219A (es) | 2005-06-08 |
Family
ID=32116298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05004219A MXPA05004219A (es) | 2002-10-25 | 2003-10-20 | Composicion farmaceutica de liberacion prolongada. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1558263B1 (enExample) |
| JP (1) | JP4584715B2 (enExample) |
| CN (1) | CN1326526C (enExample) |
| AR (1) | AR041713A1 (enExample) |
| AT (1) | ATE327759T1 (enExample) |
| AU (1) | AU2003279302B2 (enExample) |
| BR (2) | BRPI0315513B1 (enExample) |
| CA (1) | CA2501395C (enExample) |
| CO (1) | CO5700769A2 (enExample) |
| DE (1) | DE60305728T2 (enExample) |
| ES (1) | ES2265590T3 (enExample) |
| MX (1) | MXPA05004219A (enExample) |
| NO (1) | NO334158B1 (enExample) |
| NZ (1) | NZ539478A (enExample) |
| PL (1) | PL208585B1 (enExample) |
| PT (1) | PT1558263E (enExample) |
| WO (1) | WO2004037265A1 (enExample) |
| ZA (1) | ZA200502956B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007291308A1 (en) * | 2006-08-30 | 2008-03-06 | Intervet International B.V. | Pharmaceutical compositions comprising cefquinome |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤 |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| AR077320A1 (es) * | 2009-07-20 | 2011-08-17 | Intervet Int Bv | Metodo para la preparacion de particulas de cefquinoma y formulaciones farmaceuticas que las comprenden. |
| AU2012206621B2 (en) * | 2011-01-12 | 2017-04-27 | Intervet International B.V. | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
| WO2012095438A1 (en) * | 2011-01-12 | 2012-07-19 | Intervet International B.V. | Particles and suspensions of cephalosporin antibiotics |
| CN102319210B (zh) * | 2011-09-29 | 2013-05-01 | 武汉回盛生物科技有限公司 | 一种兽用长效硫酸头孢喹肟注射液及其制备方法 |
| CN104546703B (zh) * | 2013-12-10 | 2017-06-23 | 中国农业科学院饲料研究所 | 一种奶牛泌乳期用硫酸头孢喹肟乳房注入剂及其制备方法 |
| CN104000783B (zh) * | 2014-05-14 | 2017-12-05 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
| CN104873462B (zh) * | 2014-11-18 | 2017-04-05 | 中国农业科学院饲料研究所 | 一种奶牛干乳期用硫酸头孢喹肟乳房注入剂及其制备方法 |
| CN107157927A (zh) * | 2017-05-31 | 2017-09-15 | 合肥中龙神力动物药业有限公司 | 动物用硫酸头孢喹肟注射液及其制备方法 |
| CN109044970A (zh) * | 2018-11-08 | 2018-12-21 | 遂宁市中通实业集团动物药业有限公司 | 一种硫酸头孢喹肟注射液及其制备方法 |
| CN113209014A (zh) * | 2020-01-21 | 2021-08-06 | 江西邦诚动物药业有限公司 | 长效硫酸头孢喹肟混悬注射液及其制备工艺 |
| CN113952298B (zh) * | 2021-12-08 | 2023-02-17 | 江苏农牧科技职业学院 | 硫酸头孢喹肟纳米混悬液及其制备方法 |
| CN117982413B (zh) * | 2024-04-03 | 2024-06-18 | 山东恒邦中科生物工程有限公司 | 一种硫酸头孢喹肟注射液的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920819A (en) * | 1974-12-02 | 1975-11-18 | Lilly Co Eli | Nonaqueous vehicle for oral pharmaceutical suspensions |
| IE49768B1 (en) * | 1979-05-21 | 1985-12-11 | Leo Pharm Prod Ltd | 6beta-halopenicillanic acid derivatives |
| IE51846B1 (en) * | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
| GB8531609D0 (en) * | 1985-12-23 | 1986-02-05 | Beecham Group Plc | Compounds |
| JP3022692B2 (ja) * | 1992-10-13 | 2000-03-21 | 三菱マテリアル株式会社 | リーク検査装置 |
| GB9306106D0 (en) * | 1993-03-24 | 1993-05-12 | Norbrook Lab Ltd | Sustained release veterinary composition |
| DE4440141A1 (de) * | 1994-11-10 | 1996-05-15 | Hoechst Ag | Neue kristalline Cephem-Säureadditionssalze und Verfahren zu ihrer Herstellung |
| GB9907916D0 (en) * | 1999-04-07 | 1999-06-02 | Takeda Chemical Industries Ltd | Long-acting antibacterial composition |
| WO2003063877A1 (en) * | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
-
2003
- 2003-10-20 ES ES03772240T patent/ES2265590T3/es not_active Expired - Lifetime
- 2003-10-20 MX MXPA05004219A patent/MXPA05004219A/es active IP Right Grant
- 2003-10-20 JP JP2004545913A patent/JP4584715B2/ja not_active Expired - Lifetime
- 2003-10-20 BR BRPI0315513-7A patent/BRPI0315513B1/pt unknown
- 2003-10-20 AT AT03772240T patent/ATE327759T1/de not_active IP Right Cessation
- 2003-10-20 DE DE60305728T patent/DE60305728T2/de not_active Expired - Lifetime
- 2003-10-20 NZ NZ539478A patent/NZ539478A/en not_active IP Right Cessation
- 2003-10-20 PT PT03772240T patent/PT1558263E/pt unknown
- 2003-10-20 EP EP03772240A patent/EP1558263B1/en not_active Expired - Lifetime
- 2003-10-20 AU AU2003279302A patent/AU2003279302B2/en not_active Expired
- 2003-10-20 CA CA2501395A patent/CA2501395C/en not_active Expired - Fee Related
- 2003-10-20 WO PCT/EP2003/011644 patent/WO2004037265A1/en not_active Ceased
- 2003-10-20 PL PL376840A patent/PL208585B1/pl unknown
- 2003-10-20 BR BR0315513-7A patent/BR0315513A/pt active IP Right Grant
- 2003-10-20 CN CNB2003801015269A patent/CN1326526C/zh not_active Expired - Lifetime
- 2003-10-24 AR ARP030103884A patent/AR041713A1/es active IP Right Grant
-
2005
- 2005-04-04 NO NO20051654A patent/NO334158B1/no not_active IP Right Cessation
- 2005-05-23 CO CO05049742A patent/CO5700769A2/es not_active Application Discontinuation
-
2006
- 2006-01-25 ZA ZA200502956A patent/ZA200502956B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2501395A1 (en) | 2004-05-06 |
| CN1326526C (zh) | 2007-07-18 |
| DE60305728D1 (de) | 2006-07-06 |
| NO334158B1 (no) | 2013-12-23 |
| BR0315513A (pt) | 2005-08-23 |
| ZA200502956B (en) | 2006-03-29 |
| JP4584715B2 (ja) | 2010-11-24 |
| ATE327759T1 (de) | 2006-06-15 |
| NO20051654L (no) | 2005-05-24 |
| AR041713A1 (es) | 2005-05-26 |
| ES2265590T3 (es) | 2007-02-16 |
| JP2006510607A (ja) | 2006-03-30 |
| AU2003279302B2 (en) | 2008-10-16 |
| EP1558263A1 (en) | 2005-08-03 |
| CN1705483A (zh) | 2005-12-07 |
| DE60305728T2 (de) | 2006-10-12 |
| NZ539478A (en) | 2006-05-26 |
| EP1558263B1 (en) | 2006-05-31 |
| PL208585B1 (pl) | 2011-05-31 |
| CO5700769A2 (es) | 2006-11-30 |
| BRPI0315513B1 (pt) | 2017-11-28 |
| CA2501395C (en) | 2011-05-24 |
| PT1558263E (pt) | 2006-10-31 |
| WO2004037265A1 (en) | 2004-05-06 |
| AU2003279302A1 (en) | 2004-05-13 |
| PL376840A1 (pl) | 2006-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05004219A (es) | Composicion farmaceutica de liberacion prolongada. | |
| EP1569693B1 (en) | Pharmaceutical compositions having a modified vehicle | |
| JP2000513011A (ja) | 動物の耳への注射用抗生物質の投与 | |
| US6911441B2 (en) | Prolonged release pharmaceutical composition | |
| EP1317256B1 (en) | Pharmaceutical composition having modified carrier | |
| AU2001288323A1 (en) | Pharmaceutical composition having modified carrier | |
| US20020068065A1 (en) | Pharmaceutical composition having specific water activity | |
| Sayed et al. | Pharmacokinetics and tissue residues of cephradine in healthy and experimentally Salmonella entretidis infected broiler chickens | |
| WO2000061149A1 (en) | Long-acting antibacterial composition | |
| DK1569693T3 (en) | Pharmaceutical compositions with a modified vehicle | |
| HK1156876B (en) | Composition comprising an antibiotic and a corticosteroid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FG | Grant or registration |